MayTech Global Investments LLC Invests $24.42 Million in Eli Lilly and Company $LLY

MayTech Global Investments LLC purchased a new position in Eli Lilly and Company (NYSE:LLY) during the fourth quarter, Holdings Channel.com reports. The firm purchased 22,714 shares of the company’s stock, valued at approximately $24,417,000. Eli Lilly and Company comprises about 2.5% of MayTech Global Investments LLC’s investment portfolio, making the stock its 18th biggest position.

A number of other hedge funds have also modified their holdings of LLY. Cidel Asset Management Inc. increased its position in Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after buying an additional 5,591 shares during the last quarter. Spire Wealth Management increased its position in Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after buying an additional 592 shares during the last quarter. Coldstream Capital Management Inc. increased its position in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock worth $32,365,000 after buying an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC increased its position in Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after buying an additional 7,338 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its position in Eli Lilly and Company by 3.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock worth $126,022,000 after buying an additional 5,595 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on LLY. Wolfe Research reissued an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Daiwa Securities Group increased their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Rothschild & Co Redburn increased their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Finally, Leerink Partners set a $1,119.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and research notes continue to turn more upbeat on Eli Lilly’s earnings outlook, with Erste Group lifting FY2026 and FY2027 EPS estimates and Goldman Sachs reiterating a buy rating on the back of an encouraging obesity-treatment pipeline. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Eli Lilly’s strong growth story is still resonating with investors: recent coverage says the stock is in a buy zone, institutional funds are adding shares, and the company remains a leader in the GLP-1 obesity market after a big earnings beat and raised guidance. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Positive Sentiment: The company also added a new growth angle by expanding its chronic pain pipeline, including new Phase 2 trials in osteoarthritis and chronic low back pain, which could broaden Lilly’s long-term revenue base beyond obesity and diabetes. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Positive Sentiment: FDA progress for Ebglyss, including an easier once-every-eight-weeks maintenance regimen, adds another commercial catalyst and supports Lilly’s push to diversify into dermatology. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Neutral Sentiment: Lilly also unveiled an AI partnership with Abridge, aimed at speeding drug development, trial enrollment and research; that is strategically positive, but it is a longer-term story than a near-term earnings driver. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Negative Sentiment: A key overhang is growing concern that some employers may reduce or drop coverage for GLP-1 weight-loss drugs in 2027, which could pressure demand and reimbursement for Lilly’s obesity franchise. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases 2026-06-11

Eli Lilly and Company Trading Up 0.4%

Shares of NYSE:LLY opened at $1,137.01 on Monday. The company has a market cap of $1.07 trillion, a P/E ratio of 40.39, a P/E/G ratio of 1.24 and a beta of 0.53. The stock’s 50-day moving average is $998.47 and its 200-day moving average is $1,016.36. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the business posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.